Founder, President, CEO
United States of America
Michael Heffernan is the Founder, President and CEO of Collegium Pharmaceutical, Inc. He has more than 25 years of experience in the pharmaceutical and related healthcare industries. He was previously the Founder, President and CEO of Onset Dermatologics, a dermatology focused company that was spun out of Collegium to create PreCision Dermatology and was sold to Valeant (2014). Michael held prior positions as Co-Founder, President and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp and later served as President and CEO of PhyMatrix. Michael began his career at Eli Lilly and Company and served in numerous sales and marketing roles. He has also been an advisor and Investor in a number of healthcare companies. His past board memberships include; TyRx (sold to Medtronic), Cornerstone Therapeutics (sold to Chiesi), Ocata (sold to Astellas), and PreCision Dermatology. Michael is currently the Chairman of the board for Veloxis Pharmaceuticals (OMX:VELO) and serves on the board for Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX). Michael earned his B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.